Particulars (Rs. in cr) | Q4FY25 | Q4FY24 | YoY (%) | Q3FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 308.00 | 225.00 | 37.00% | 275.00 | 12.00% |
EBITDA | 85.00 | 43.00 | 98.00% | 68.00 | 25.00% |
EBITDA Margin (%) | 27.60% | 19.11% | 849 bps | 24.73% | 287 bps |
PAT | 63.00 | 26.00 | 144.00% | 45.00 | 40.00% |
EPS (%) | 7.80 | 3.43 | 127.00% | 5.61 | 39.00% |
Source: Company Filings; stockaxis Research
Q4FY25 Result Highlights
AMI Organics showcased robust financial performance for the quarter ended Q4FY25.
Consolidated net sales rose 37% YoY to Rs.308 cr as compared to Rs.225 cr registered
in the same quarter of preceding fiscal driven by healthy growth in the pharma intermediate
sales which jumped to Rs.270 cr (up 14% QoQ and 44% YoY). This jump could be due
to a jump in CDMO sales to Fermion. Specialty chemicals revenue fell slightly to
Rs. 36 cr and Rs.36 cr in Q3FY25, down 1% QoQ while up 1% YoY). In Q4FY25, pharma
intermediate EBITDA margin was 24.5% and speciality chemicals margin was 14.7%.
The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ.
On the operational front, consolidated EBITDA witnessed remarkable growth of 97%
YoY to Rs.85 cr while EBITDA margin for the quarter was at 27.5% on account of a
sharp jump in CDMO sales and resultant positive operating leverage. PAT registered
a staggering growth of 144% to Rs.63 cr.
Guidance
Capex
The management has indicated a capex of Rs.200 cr for FY26,
comprising spillover capex of Rs.130 cr for electrolyte additives and the rest for
maintenance and a pilot plant at Sachin. This will be fully funded through QIP proceeds
and internal accruals. Capex for FY25 stood at Rs.195 cr primarily for the Ankleshwar
facility, solar plant and electrolyte additives capacity. Block 1 at Ankleshwar
is set to be commissioned in Q1FY26 with a 10.8MW solar plant already commissioned
at the Sachin facility.
Other Key Highlights
Ami Organics delivered an impressive set of earnings for the quarter ended Q4FY25. We like the company given its wide product portfolio in pharmaceutical intermediates, diversification efforts into other specialty chemical spaces, strong client relations across geographies, and robust financials. It is well placed to tap the opportunity in the fast-growing specialty chemical market by leveraging its strong R&D capabilities and expanding its product portfolio. We believe that the near to medium-term growth would be driven by advanced intermediates for pharma innovators. AMI is present across the value chain of the intermediates business, from supplying NCE to innovators, to providing a wide range of products with different routes of synthesis and different levels of intermediates. As one of the biggest manufacturers of intermediates for the target therapies, AMI is in a unique position to cross-sale new molecules to existing clients. Their unique business model positions them perfectly to be the preferred suppliers for innovators as well as big generic pharma companies. The company is gradually executing Fermion’s contract in the first block of the Ankleshwar unit. It is meant for advanced pharmaceutical intermediates for the API Darolutamide and would finally ramp up in FY26. Hence, we believe Ami Organics is well-placed to capitalize on domestic and global opportunities.
We believe that the pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, positioning the company favourably for sustained long-term growth. Management has guided for 25% growth for FY26. Strong sales from Fermion contracts, the commercialization of an additional CDMO contract, significant expansion in the generic intermediate portfolio, and contributions from electrolyte additives projected from FY26E are some growth drivers for the company. We believe that the near-term growth would be driven by the advanced intermediates business. Operating margins are expected to improve further in FY26 due to operating leverage and also due to energy cost savings, following the setting up of a captive solar plant. At CMP of Rs.1161.80, the stock is trading at 33x FY27E. We maintain HOLD rating on the stock.
Particulars (Rs. in cr) | Q4FY25 | Q4FY24 | YoY (%) | Q3FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 308.00 | 225.00 | 37.00% | 275.00 | 12.00% |
COGS | 162.00 | 135.00 | 20.00% | 148.00 | 9.00% |
Gross Profit | 146.00 | 90.00 | 62.00% | 127.00 | 15.00% |
Gross Margin (%) | 47.40% | 40.00% | 740 bps | 46.18% | 122 bps |
Employee benefit expenses | 23.00 | 17.00 | 35.00% | 22.00 | 5.00% |
Other expenses | 38.00 | 30.00 | 27.00% | 37.00 | 3.00% |
EBITDA | 85.00 | 43.00 | 98.00% | 68.00 | 25.00% |
EBITDA Margin (%) | 27.60% | 19.11% | 849 bps | 24.73% | 287 bps |
Depreciation expenses | 7.00 | 5.00 | 40.00% | 6.00 | 17.00% |
EBIT | 78.00 | 38.00 | 105.00% | 62.00 | 26.00% |
Finance costs | 0.60 | 2.00 | -70.00% | 0.70 | -14.00% |
Other Income | 6.00 | 1.00 | 500.00% | 2.00 | 200.00% |
PBT | 83.00 | 37.00 | 125.00% | 63.00 | 32.00% |
Tax expenses | 20.00 | 12.00 | 67.00% | 18.00 | 11.00% |
PAT | 63.00 | 26.00 | 144.00% | 45.00 | 40.00% |
EPS (%) | 7.80 | 3.43 | 127.00% | 5.61 | 39.00% |